Bioceltix S.A.
BCX.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.43 | -0.84 | -0.16 | -0.81 |
| FCF Yield | -4.52% | -4.31% | -6.38% | -2.45% |
| EV / EBITDA | -25.97 | -25.98 | -14.79 | -40.34 |
| Quality | ||||
| ROIC | -47.16% | -146.51% | -242.32% | -88.95% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.19 | 1.08 | 0.89 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -18.24% | -84.14% | -104.08% | -165.19% |
| Safety | ||||
| Net Debt / EBITDA | 2.34 | 0.69 | 0.45 | 1.40 |
| Interest Coverage | -74.08 | -470.16 | -307.02 | -270.74 |
| Efficiency | ||||
| Inventory Turnover | 41.03 | 120.47 | 0.00 | 0.00 |
| Cash Conversion Cycle | -939.59 | -421.24 | -786.01 | -278.67 |